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Available online 24 December 2015“Forgiveness” – the difference between a drug's postdose duration of action and its prescribed dosing interval –
estimates themargin of therapeutic effect following amissed dose. Because thismargin presumably decreases as
dosing becomes less frequent, QDdosing of an antiepileptic drug (AED) is expected to be less forgiving thanmore
frequent (e.g., BID) dosing of that same AED. However, if the AED is reformulated as an extended-release (XR)
preparation, drug input may be prolonged relative to its immediate-release (IR) counterpart. It therefore stands
to reason that forgiveness could be increased by an XR AED that extends the period during which therapeutic
plasma concentrations aremaintained if a dose ismissed. Computer simulationwas used to estimate forgiveness
for an IR formulation of a hypothetical AED and its XR counterparts reformulated for less frequent dosing. Simu-
lations determined forgiveness when the hypothetical IR AEDwas dosed TID, BID, and QD andwhen suitably de-
signed XR formulations were dosed BID and QD. Simulations showed that forgiveness for an XR formulation can
equal or exceed that for an IR formulation dosed more frequently.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Patients and physicians agree that efﬁcacy and safety/tolerability are
the most important attributes when selecting an antiepileptic drug
(AED). However, for patients, the next most important characteristic is
dosing convenience [1], an important determinant of patient adherence
[2]. Because extended-release (XR) formulations offer the potential for
more constant plasma concentration–time proﬁles with less frequent
dosing, they may positively impact tolerability, adherence, and there-
fore, overall effectiveness. It is therefore not surprising that most AEDs
that were initially administered in multiple daily doses as immediate-
release (IR) formulations are now available as XR formulations for
patients with epilepsy, including phenytoin, carbamazepine, valproate,
lamotrigine, topiramate, oxcarbazepine, and levetiracetam. Although
they use different technologies to slow/control drug release and thereby
prolong drug absorption, XR formulations are designed to minimize
plasma concentration ﬂuctuations over the course of a day despite less
frequent dosing than their IR counterparts [3]. However, even with
less frequent dose administration, adherence can be imperfect as pa-
tients take doses late or miss doses altogether [4]. Recognition thatls, Inc., 1550 East Gude Drive,
llock), sbrittain@supernus.com
University School of Medicine,
. This is an open access article underless frequent dosingwith XR formulations can be associatedwith better
outcomes is often tempered by expectations that QD dosing, for exam-
ple, is not as “forgiving” as BID dosing, implying that a late or missed
dose of an XR AED is more likely to compromise seizure control than a
dose of its more frequently administered IR counterpart [5–7].
“Drug forgiveness” (F) – a measure of the margin in therapeutic
effect if a dose is missed – is conceptualized as the difference between
a drug's postdose duration of action (D) and the prescribed dosing inter-
val (I), i.e., F = D− I [8]. The perception that an XR AED would invari-
ably be less forgiving than its more frequently administered IR
counterpart assumes that duration of action is constant, as if it is simply
an intrinsic characteristic of the molecule.
The increased availability of XRAEDsmerits a closer look at postdose
duration of action and its impact on forgiveness when dosing frequency
changes. To that end, we used PKmodeling and simulation to determine
plasma concentration–time proﬁles for a hypothetical AED adminis-
tered as an IR formulation and as two XR counterparts appropriately
reformulated for less frequent daily dosing. Based on plasma concentra-
tion–time proﬁles and a threshold pharmacokinetic–pharmacodynamic
(PK/PD) model, postdose duration of action (D) was determined,
allowing forgiveness (F) to be calculated.
2. Methods
For the hypothetical AED, modeling assumed that the PK character-
istics of IR and XR formulations were identical in terms of elimination
half-life (8.7 h), total daily dosage (180 mg), and systemic parametersthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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PK characteristic assumed to be different between IR and XR formula-
tions. Absorption rate was assumed to be limited by the rate of drug
release from the formulation and was modeled with a ﬁrst-order ab-
sorption rate constant (ka). For the IR formulation, ka was kept constant,
regardless of the simulated dose interval (8, 12, or 24 h). For XR formu-
lations, ka reﬂected the formulation's customization to release drug at a
rate appropriate for the desired dosing interval (XRBID: 12 h; XRQD:
24 h).
Concentration vs. time curves were simulated using a script in R
(www.R-Project.org) for a one-compartment model with ﬁrst-order
elimination and ﬁrst-order absorption. Simulations were performed
for a hypothetical IR formulation (ka = 5/h) dosed 60 mg TID (I =
8 h), 90 mg BID (I = 12 h), and 180 mg QD (I = 24 h) and for two hy-
pothetical XR formulations dosed 90 mg BID for XRBID (ka = 0.5/h; I =
12 h) and 180 mg QD for XRQD (ka = 0.1/h; I = 24 h). Concentration–
time curves were used to determine postdose duration of action when
dosing was abruptly stopped, where D was deﬁned as the interval be-
tween the time of the last administered dose and the time at which
plasma AED concentration fell below a hypothetical minimum effective
concentration, i.e., the therapeutic threshold. Forgiveness in each simu-
lation was calculated as F = D− I.
3. Results
Fig. 1 shows simulated concentration–time curves for both IR and
XR formulations. Regardless of the formulation, duration of action in-
creased when the total daily dose of 180 mg was administered in in-
creasingly larger individual dosages (i.e., 60, 90, or 180 mg per dose)
in conjunction with less frequent dosing, i.e., longer dose intervals
(I = 8, 12, or 24 h).
Fig. 1 (panels A through C) shows simulated concentration–time pro-
ﬁles for the IR formulation dosed TID, BID, and QD. Based on these simu-
lations, D increased from 18 h with TID dosing to 24.5 h with QD dosing.
However, the small increases in postdose duration of action did not
offset the impact of longer intervals between doses. The forgivenessD=18
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8 h) to 0.5 h when dosed QD (I = 24 h) (Table 1).
Fig. 1 (panels D and E) shows simulated concentration–time
proﬁles for the two XR formulations customizedwith slower absorption
rates for BID and QD administration. The simulations predicted that for
a given dosing regimen, the XR formulations had longer postdose
duration of action than the IR formulation (Fig. 1B vs. Fig. 1D; Fig. 1C
vs. Fig. 1E). Accordingly, the XR formulations had longer forgiveness in-
tervals (Table 1).
4. Discussion
With IR formulations, peak drug concentration occurs shortly after
administration, resembling the plasma concentration–time proﬁle of
a parenterally administered drug. Thus, elimination half-life often de-
termines dosing interval for an orally administered IR drug while the
absorption phase is typically disregarded. However, in the case of oral
XR formulations, plasma concentration–time proﬁles diverge signiﬁ-
cantly from those with parenteral dosing such that half-life alone no
longer deﬁnes the dosing interval. Since the rate of drug release from
an XR formulation is controlled, absorption continues long after dosing,
with the peak concentration occurring much later. The optimal dosing
interval with an XR formulation is therefore determined by the inter-
play between controlled drug release and drug elimination. A well-
designed XR product maintains effective drug levels longer than its IR
counterpart, increasing postdose duration of action and effectively ex-
tending the XR formulation's half-life.
The simulations with an IR AED formulation reported here demon-
strate the dose dependency of postdose duration of action. With the IR
formulation, the only parameters that changed in each dosing simula-
tion were the magnitude of the dose and dose interval. Compared
with TID dose frequency, which was consistent with the hypothetical
AED's half-life of 8.7 h, the larger doses with BID and QD administration
maintained therapeutic plasma concentrations for longer periods. How-
ever, increased duration of action with larger doses administered BID
and QD relative to TID administration came at the expense of greaterThreshold
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Table 1
Forgiveness calculation (F = D − I) for hypothetical AED as IR or customized XR
formulations.
Formulation Interval,
h (I)
Duration,
h (D)
Forgiveness,
h (F)
Immediate-release (IR), ka = 5 h−1 8 18 10
12 20 8
24 24.5 0.5
Extended-release (XR) designed for
BID dosing (XRBID), ka = 0.5 h−1
12 22 10
Extended-release (XR) designed for
QD dosing (XRQD), ka = 0.1 h−1
24 37 13
23J.M. Pellock, S.T. Brittain / Epilepsy & Behavior 55 (2016) 21–23ﬂuctuation [(Cmax− Cmin) / Cavg], producing not only higher, potentially
more toxic peak concentrations but also lower trough concentrations
that led to a smaller therapeutic margin and shorter forgiveness [9].
The simulations with the XR AED formulations illustrate the inﬂu-
ence of a formulation's drug release proﬁle, characterized by the absorp-
tion rate constant (ka), on postdose duration of action. In simulations of
BID and QD dosing, ka was the only parameter that differed for XR for-
mulations relative to the IR formulation. When the rate of drug release
was customized to the desired dosing frequency, postdose duration of
action and forgivenesswere longerwith theXR formulations. Compared
with TID dosing of the IR formulation, the forgiveness interval was the
same (XRBID) or even longer (XRQD) with the XR AEDs.
These simulations were designed to explore forgiveness as the dos-
ing interval of a hypothetical IR AED is lengthened without reformula-
tion compared with XR formulations that are speciﬁcally designed to
achieve a desired dosing frequency. The XR formulations combined a
larger total dose with a slower release rate. This design extended
postdose duration of action and offset the increased dosing interval
to produce equivalent or longer forgiveness periods. For the IR for-
mulation, the effect of the larger dose alone was not sufﬁcient to justify
less frequent dosing. Although TID administration of the IR AED was
the only simulation in which the forgiveness period was longer than
the dosing interval, this outcome arises because of the interplay of the
parameters (e.g., ka, half-life, threshold) selected for modeling and
simulation.
A limitation of these simulations is the use of time to subtherapeutic
plasma concentration as a measure of postdose duration of action, par-
ticularly since mechanism(s) of action and duration of an AED's thera-
peutic effect are generally not known. Moreover, the breakpoint
between therapeutic and subtherapeutic concentrations is highly indi-
vidualized and inﬂuenced by a multitude of factors such as genetics,
age, and disease severity/refractoriness.
This study illustrates the potential value of computer modeling
and simulation in exploring drug dosing. For several AEDs, including
some with XR formulations, modeling and simulation has been a tool
for determining dosing strategies when doses are taken late or missed
completely [10–13]. As our simulations illustrate, appropriately de-
signed XR AEDs can be as forgiving, if not more so, as their more fre-
quently dosed IR counterparts.5. Conclusion
Extended-release formulations of AEDs offer potential advantages
over their IR counterparts in terms of simpliﬁed dosing, improved toler-
ability, and increased adherence. The sum of these advantages may be
greater overall effectiveness and better outcomes for patients with epi-
lepsy. The simulations illustrated here should allay concerns that a
missed dose of an appropriately designedXR formulation poses, a priori,
a greater risk to seizure control than amissed dose of its IR counterpart.
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